Cambridge Investment Research Advisors Inc. Has $28.19 Million Stock Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Cambridge Investment Research Advisors Inc. decreased its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 10.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 462,142 shares of the biopharmaceutical company's stock after selling 51,585 shares during the quarter. Cambridge Investment Research Advisors Inc.'s holdings in Bristol Myers Squibb were worth $28,186,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Pinney & Scofield Inc. acquired a new position in Bristol Myers Squibb during the 4th quarter worth $25,000. Park Square Financial Group LLC acquired a new stake in Bristol Myers Squibb in the fourth quarter worth about $26,000. Global Wealth Strategies & Associates lifted its position in Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares during the period. Transce3nd LLC bought a new position in shares of Bristol Myers Squibb in the 4th quarter valued at about $28,000. Finally, Fairway Wealth LLC acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $28,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Up 0.2%

Shares of BMY stock traded up $0.12 during trading on Tuesday, reaching $47.04. The company's stock had a trading volume of 14,538,084 shares, compared to its average volume of 12,974,865. Bristol Myers Squibb Company has a one year low of $39.35 and a one year high of $63.33. The business has a fifty day moving average price of $48.06 and a 200-day moving average price of $54.16. The company has a market cap of $95.72 billion, a price-to-earnings ratio of 17.62, a price-to-earnings-growth ratio of 1.39 and a beta of 0.38. The company has a quick ratio of 1.17, a current ratio of 1.28 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company's revenue for the quarter was down 5.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($4.40) EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd will be given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.27%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio (DPR) is 92.88%.

Analysts Set New Price Targets

A number of analysts have commented on BMY shares. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. William Blair reissued a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. UBS Group decreased their target price on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Finally, Piper Sandler initiated coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $58.00.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction on Friday, April 25th. The shares were purchased at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.07% of the company's stock.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.